X4 Pharmaceuticals Reports Q2 2026 Results and Advances Mavorixafor Development
BOSTON, August 6, 2026 X4 Pharmaceuticals reported second quarter 2026 financial results while highlighting continued progress in the global...
Hematology
Advertisement
Damora Therapeutics Launches Phase 1 Trial of DMR-001
WALTHAM, Mass., Aug. 5, 2026 Damora Therapeutics, Inc. has announced the initiation of the global Phase 1/1b CLARITY-101 clinical...
Karyopharm Eyes Accelerated FDA Approval for Selinexor
NEWTON, Mass., July 30, 2026 Karyopharm Therapeutics Inc. plans to submit a supplemental New Drug Application (sNDA) to the...
CREATE, Monash Partner to Advance In Vivo CAR-T Platform
CAMBRIDGE, Mass., July 31, 2026 CREATE Medicines has announced a strategic research collaboration and exclusive worldwide licensing agreement with...
Curis Advances TakeAim CLL Trial with First Patients Dosed
LEXINGTON, Mass., July 30, 2026 Curis, Inc. has reached an important clinical milestone by successfully dosing the first five...
Advertisements
Johnson & Johnson Advances Myeloma Care with TECVAYLI and TALVEY
RARITAN, N.J., July 23, 2026 Johnson & Johnson has announced positive topline results from the Phase 3 MonumenTAL-6 clinical...
Genmab and AbbVie Clarify EPCORE DLBCL-1 Phase 3 Results
COPENHAGEN, Denmark and NORTH CHICAGO, Ill., July 23, 2026 Genmab and AbbVie have issued a clarification regarding the Phase...
Nuvectis Pharma Announces China Approval of Ciprocopan for PNH
FORT LEE, N.J., July 23, 2026 Nuvectis Pharma, Inc. announced that ciprocopan (NXP100) has received marketing approval from China’s...
Biohaven Unveils Promising BHV-1530 Cancer Data at ESMO
NEW HAVEN, Conn., July 20, 2026 Biohaven Ltd. has announced that new Phase I clinical data for BHV-1530, its...
Halozyme and Incyte Join Forces to Improve Cancer Drug Delivery
SAN DIEGO, July 20, 2026 Halozyme Therapeutics has entered into a global collaboration and license agreement with Incyte to...
Advertisement
